ArticleOncotarget2017

Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.

Keita Masuzawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.